Ignyta Names Senior VP, Chemistry & Manufacturing
This article was originally published in Scrip
Ignyta, Inc., a precision oncology biotechnology company, has appointed Dr Valerie Harding to the newly created role of senior vice-president, chemistry, manufacturing, and controls. Harding joins Ignyta from Pfizer, where she held many roles including vice-president of product differentiation, vice-president of drug product design and vice-president of pharmaceutical development. Prior to Pfizer, Harding spent three years as a scientist and team leader at Boots and Company, preceded by three years as a tutor and researcher at the University of Nottingham's School of Pharmacy. Harding holds a Ph.D. in Pharmaceutical Microbiology from the University of Nottingham and a B.S. in Pharmacy from the University of London.
You may also be interested in...
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...
It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.